Lanthio Pharma, MorphoSys deal

MorphoSys acquired the remaining 80% of Lanthio it did not already own for EUR20 million ($22.3 million). MorphoSys gains LP2, a selective angiotensin II type 2 (AT2) receptor (ATGR2) agonist lantip...